Navigation Links
Risk of Leukemia with Multiple Sclerosis Drug Higher Than Thought
Date:4/30/2009

SEATTLE, April 30 /PRNewswire-USNewswire/ -- The risk of developing leukemia as a side effect of a drug for multiple sclerosis (MS) is higher than previously reported, according to a study presented as part of the Late-breaking Science Program at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 - May 2, 2009.

Mitoxantrone is an immunosuppressant drug approved by the FDA for treatment of several forms of advancing MS. It is one of only two drugs that has been shown to benefit people with secondary progressive MS who are having attacks. However, the drug can cause heart damage at high total doses. Due to this, the lifetime cumulative dose is equal to about eight to 12 doses over two to three years.

Previous studies have also shown that the people with MS treated with the drug have an increased risk of developing leukemia. Those studies showed that acute leukemia occurred in .07 percent to .25 percent of MS patients taking mitoxantrone. Today's retrospective study of 2,854 Italian people with MS receiving the drug found that leukemia occurred in .74 percent.

"This rate is significantly higher than what has been previously reported," said study author Vittorio Martinelli, MD, of University Vita-Salute in Milan, Italy. "The potential risk of leukemia should be carefully considered against the potential benefits of mitoxantrone treatment on every single patient."

The study participants all had at least one cycle of mitoxantrone treatment and were observed for at least one year. A total of 21 people developed leukemia, eight of whom died. The people who developed leukemia had more treatment cycles than those who did not develop leukemia -- 8.6 cycles versus 7.2 cycles. They also had a greater cumulative dose of mitoxantrone.

The leukemia occurred an average of three years after the first use of the drug and an average of 18 months after the end of treatment.

"It is vital that all MS patients treated with mitoxantrone undergo prolonged and careful hematological follow-up to check for acute leukemia," Martinelli said.

The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. For more information about AAN, visit www.aan.com.

The AAN 61st Annual Meeting, the world's largest gathering of neurology professionals, takes place April 25-May 2, 2009, in Seattle. Visit www.aan.com/am for more information.


'/>"/>
SOURCE American Academy of Neurology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers find drug that inhibits acute leukemia cell growth
2. Vince Papale and Eagles Fly for Leukemia Tee Up for a Cure at May 4, 2009 Celebrity Golf Classic and Auction
3. The Nations Triathlon to Benefit The Leukemia & Lymphoma Society is Sold Out But Theres Still a Way In!
4. Mayo Clinic-led researchers confirm gene variants associated with the most common adult leukemia
5. Experimental agents may prevent radiation-induced leukemia
6. New biomarker may predict leukemia aggressiveness
7. Success of Colorful School Supply Collection Inspired by Leukemia Patient Kicks off Second Year
8. Enhancing the effects of the drug used to treat chronic myeloid leukemia
9. Scientists Identify Key Gene That Protects Against Leukemia
10. Families of Children Affected by Leukemia Get Boost of Support Thanks to Gift From Chrysler Jeep Superstores
11. Gap Inc., The Leukemia & Lymphoma Society Encourage Shoppers to Support Cancer-Fighting Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is ... to cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, ... the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic ...
(Date:5/5/2016)... ... May 05, 2016 , ... Spring Fertility , the ... and with egg freezing, today announced the grand opening of its first location ... care, Spring Fertility offers both fertility preservation (egg, sperm, embryo, and testicular and ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors (UBA), ... as the latest addition to its family of Partner Firms. Headquartered in Mount ... wellness, human resources, and health care consumerism specialists. , “Partnering with UBA will ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/5/2016)... ... 05, 2016 , ... Tim Dieter has announced the latest ... Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center on behalf of ... Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . , Veteran’s Freedom ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... -- Pharmaceutical giant Johnson & Johnson has ... who says its talc-based powder products caused ovarian cancer. ... $5 million in compensatory damages and $50 million in ... ) , This is the second in ... the same court awarded $72 million to the family ...
Breaking Medicine Technology: